Boston Trust Walden Corp Sells 78,765 Shares of Haemonetics Corporation $HAE

Boston Trust Walden Corp reduced its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 13.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 501,885 shares of the medical instruments supplier’s stock after selling 78,765 shares during the quarter. Boston Trust Walden Corp’s holdings in Haemonetics were worth $28,286,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Peregrine Capital Management LLC lifted its holdings in Haemonetics by 47.4% during the 1st quarter. Peregrine Capital Management LLC now owns 42,163 shares of the medical instruments supplier’s stock valued at $2,376,000 after purchasing an additional 13,553 shares during the last quarter. Inspire Investing LLC lifted its position in Haemonetics by 56.2% during the first quarter. Inspire Investing LLC now owns 9,099 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 3,272 shares during the period. Skylands Capital LLC grew its stake in Haemonetics by 80.5% during the first quarter. Skylands Capital LLC now owns 65,825 shares of the medical instruments supplier’s stock worth $3,710,000 after buying an additional 29,350 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Haemonetics during the first quarter worth about $247,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Haemonetics by 17.3% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock valued at $47,400,000 after purchasing an additional 124,020 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research reports. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a research note on Friday, May 8th. JPMorgan Chase & Co. reduced their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Mizuho increased their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Barrington Research lowered their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Finally, BTIG Research reiterated a “buy” rating and set a $84.00 target price on shares of Haemonetics in a research report on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.33.

Haemonetics Trading Down 0.2%

Shares of Haemonetics stock opened at $74.93 on Friday. The firm has a market cap of $3.41 billion, a PE ratio of 37.09, a P/E/G ratio of 1.51 and a beta of 0.52. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock has a fifty day moving average price of $66.82 and a 200-day moving average price of $66.55.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 5.22 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.